源自大肠埃希菌的16型和18型人乳头瘤病毒双价疫苗的表征
研究开发了一种由大肠埃希菌表达系统生产的HPV16/18双价候选疫苗,采用N端截短和可溶性非融合表达策略在30L、100L和500L规模下制备L1-only病毒样颗粒(VLP),并确认批次一致性。冷冻电镜三维重建显示VLP呈T=7二十面体排列,形态和大小与天然病毒粒子相似。该疫苗免疫原性与已上市疫苗相当,生产工艺稳健且可放大,有望在全球范围内作为人群免疫策略提高可及性。
要点
- 大肠埃希菌表达的HPV16/18双价候选疫苗可规模化生产,30L、100L、500L规模批次一致。
- 冷冻电镜显示HPV16/18 VLP呈T=7二十面体排列,形态大小与天然病毒粒子相似。
- 该疫苗免疫原性与已上市疫苗相当。
核心结论
- 由大肠埃希菌表达系统生产的HPV16/18双价疫苗工艺稳健且可放大,有望作为人群免疫策略在全球范围内提高可及性。
研究设计与样本
- 研究采用N端截短和可溶性非融合表达两种策略,在大肠埃希菌中生产HPV16和HPV18 L1-only病毒样颗粒(VLP)并制备双价候选疫苗。
主要发现
- 在30L、100L和500L中试放大规模中确认了双价候选疫苗的批次一致性。
- 冷冻电镜三维重建显示HPV16和HPV18 VLP呈T=7二十面体排列,形态和大小与天然病毒粒子相似。
- 该HPV16/18双价疫苗免疫原性与已上市疫苗相当。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Human papillomavirus (HPV) types 16 and 18 account for approximately 70% of cervical cancer worldwide. Neutralizing HPV prophylactic vaccines offer significant benefit, as they block HPV infection and prevent subsequent disease. However, the three licensed HPV vaccines that cover these two genotypes were produced in eukaryotic cells, which is expensive, particularly for low-income countries where HPV is highest. Here, we report a new HPV16 and -18 bivalent candidate vaccine produced from Escherichia coli. We used two strategies of N-terminal truncation of HPV L1 proteins and soluble non-fusion expression to generate HPV16 and HPV18 L1-only virus-like particles (VLPs) in a scalable process. Through comprehensive characterization of the bivalent candidate vaccine, we confirm lot consistency in a pilot scale-up of 30L, 100L and 500L. Using cryo-EM 3D reconstruction, we found that HPV16 and -18VLPs present in a T=7 icosahedral arrangement, similar in shape and size to that of the native virions. This HPV16/18 bivalent vaccine shares comparable immunogenicity with the licensed vaccines. Overall, we show that the production of a HPV16/18 bivalent vaccine from an E. coli expression system is robust and scalable, with potentially good accessibility worldwide as a population-based immunization strategy.
引用
- Gu Y, Wei M, Wang D, et al. Characterization of an Escherichia coli-derived human papillomavirus type 16 and 18 bivalent vaccine. Vaccine. 2017. PMID: 28736197. doi:10.1016/j.vaccine.2017.06.084
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。